1-4 of 4
Ashley Hamilton, BSc
Close
Sort by
Journal Articles

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

Mhairi Copland, MD, Linda Richmond, BSc, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Junia V. Melo, MD, PhD, Tessa L. Holyoake, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 739.
https://doi.org/10.1182/blood.V108.11.739.739
Published: 2006
Journal Articles

BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).

Mhairi Copland, MD, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Valerie Brunton, PhD, Tessa L. Holyoake, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 693.
https://doi.org/10.1182/blood.V106.11.693.693
Published: 2005
Journal Articles

Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro , but Does Not Eradicate Quiescent CML Stem Cells.

Mhairi Copland, MD, Ashley Hamilton, BSc, Janet W. Baird, PhD, Martin Barow, PhD, Elaine K. Allan, BSc, Lucy J. Elrick, PhD, Tessa L. Holyoake, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 695.
https://doi.org/10.1182/blood.V106.11.695.695
Published: 2005
Journal Articles

Imatinib Mesylate Does Not Inhibit BCR-ABL Kinase Activity in CML Stem Cells In Vitro .

Lucy J. Elrick, PhD, Ashley Hamilton, BSc, Michael W. Deininger, MD PhD, Tessa L. Holyoake, MD PhD
Journal: Blood
Blood (2004) 104 (11): 1979.
https://doi.org/10.1182/blood.V104.11.1979.1979
Published: 2004